Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.
Logos Capital, Woodline, and Acuta Capital, amongst others. The cash will be used for further clinical development of Enliven’s two lead candidates, BCR-ABL inhibitor ELVN-001 for chronic ...
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback